When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Levosimendan - Wikipedia

   en.wikipedia.org/wiki/Levosimendan

   Levosimendan / ˌ l iː v oʊ s aɪ ˈ m ɛ n d ən / is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Orion Corporation). Overall the drug has a two fold mechanism of action.

3. Alcoholic cardiomyopathy - Wikipedia

   en.wikipedia.org/wiki/Alcoholic_cardiomyopathy

   Alcoholic cardiomyopathy (ACM) is a disease in which the long-term consumption of alcohol leads to heart failure. [1] ACM is a type of dilated cardiomyopathy. The heart is unable to pump blood efficiently, leading to heart failure. It can affect other parts of the body if the heart failure is severe.

4. Heart failure - Wikipedia

   en.wikipedia.org/wiki/Heart_failure

   Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to fill with and pump blood.. Although symptoms vary based on which side of the heart is affected, HF typically presents with shortness of breath, excessive fatigue, and bilateral leg swelling. [3]

5. Management of heart failure - Wikipedia

   en.wikipedia.org/wiki/Management_of_heart_failure

   Sleep apnea is an under-recognized risk factor for heart failure. Uncontrolled sleep apnea may increase the risk of heart failure by up to 140%. [4] Weight reduction – through physical activity and dietary modification, as obesity is a risk factor for heart failure and left ventricular hypertrophy. Effective weight management has been shown ...

6. Cardiotonic agent - Wikipedia

   en.wikipedia.org/wiki/Cardiotonic_agent

   Cardiotonic agents are typically employed as short-term and non-routine therapies for heart failure patients. [71] They are specifically reserved for those with contractile dysfunction in the left ventricles (lower chambers of the heart), low cardiac output, and low blood pressure, placing them at risk of inadequate organ perfusion. [72]

7. External counterpulsation - Wikipedia

   en.wikipedia.org/wiki/External_counterpulsation

   The FDA approved the CardiAssist ECP system for the treatment of angina, acute myocardial infarction and cardiogenic shock under a 510(k) submission in 1980 [1] [failed verification] Since then, additional ECP devices have been cleared by the FDA for use in treating stable or unstable angina pectoris, acute myocardial infarction, cardiogenic shock, and congestive heart failure.